Julie Zhen Qin Wu

Array ( [id] => 10461180 [patent_doc_number] => 20150346195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-03 [patent_title] => 'SCREENING OF CONJUGATED ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/414432 [patent_app_country] => US [patent_app_date] => 2013-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 43576 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14414432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9421235 [patent_doc_number] => 20140105886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-17 [patent_title] => 'ASSOCIATION OF BIOMARKERS WITH PATIENT OUTCOME' [patent_app_type] => utility [patent_app_number] => 13/938007 [patent_app_country] => US [patent_app_date] => 2013-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 11199 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13938007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10262320 [patent_doc_number] => 20150147316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-28 [patent_title] => 'CD33 ANTIBODIES AND USE OF SAME TO TREAT CANCER' [patent_app_type] => utility [patent_app_number] => 14/401837 [patent_app_country] => US [patent_app_date] => 2013-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 20936 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14401837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11226120 [patent_doc_number] => 09453836 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-27 [patent_title] => 'Use of modulators of CCR5 in the treatment of cancer and cancer metastasis' [patent_app_type] => utility [patent_app_number] => 13/893791 [patent_app_country] => US [patent_app_date] => 2013-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 105 [patent_no_of_words] => 24321 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13893791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10103882 [patent_doc_number] => 09139656 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-22 [patent_title] => 'TEM-1 diagnostic antibodies' [patent_app_type] => utility [patent_app_number] => 13/804730 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 30674 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13804730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9518210 [patent_doc_number] => 20140154702 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-05 [patent_title] => 'Methods For Treating Cancer Using Combination Therapies' [patent_app_type] => utility [patent_app_number] => 13/803392 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 37724 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13803392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9408005 [patent_doc_number] => 20140099257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-10 [patent_title] => 'Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability' [patent_app_type] => utility [patent_app_number] => 13/803166 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 5322 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13803166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9160946 [patent_doc_number] => 20130309223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-21 [patent_title] => 'CD33 Antibodies And Use Of Same To Treat Cancer' [patent_app_type] => utility [patent_app_number] => 13/804227 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 20074 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13804227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11219123 [patent_doc_number] => 09447452 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-20 [patent_title] => 'Selective oxidation of 5-methylcytosine by TET-family proteins' [patent_app_type] => utility [patent_app_number] => 13/795739 [patent_app_country] => US [patent_app_date] => 2013-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 89 [patent_no_of_words] => 61443 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13795739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9015548 [patent_doc_number] => 20130230512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-05 [patent_title] => 'INHIBITORS OF THE ATB(0,+) TRANSPORTER AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/792637 [patent_app_country] => US [patent_app_date] => 2013-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 26153 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13792637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9448947 [patent_doc_number] => 20140120116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-01 [patent_title] => 'TREATMENT OF CANCER USING SMAD3 INHIBITOR' [patent_app_type] => utility [patent_app_number] => 13/779090 [patent_app_country] => US [patent_app_date] => 2013-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8572 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13779090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9082156 [patent_doc_number] => 20130267686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-10 [patent_title] => 'BISPECIFIC ANTIBODIES COMPRISING A DISULFIDE STABILIZED - FV FRAGMENT' [patent_app_type] => utility [patent_app_number] => 13/773167 [patent_app_country] => US [patent_app_date] => 2013-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 20153 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13773167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8977349 [patent_doc_number] => 20130210779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'METHOD OF IDENTIFYING TRIPLE NEGATIVE BREAST CANCER' [patent_app_type] => utility [patent_app_number] => 13/768577 [patent_app_country] => US [patent_app_date] => 2013-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 18244 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13768577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8940407 [patent_doc_number] => 20130190204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-25 [patent_title] => 'MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR' [patent_app_type] => utility [patent_app_number] => 13/758832 [patent_app_country] => US [patent_app_date] => 2013-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 16772 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13758832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11548504 [patent_doc_number] => 09617336 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-11 [patent_title] => 'C10RF32 antibodies, and uses thereof for treatment of cancer' [patent_app_type] => utility [patent_app_number] => 14/360694 [patent_app_country] => US [patent_app_date] => 2013-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 50 [patent_no_of_words] => 62033 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 408 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14360694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8939490 [patent_doc_number] => 20130189287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-25 [patent_title] => 'ENZYMATIC CONJUGATION OF POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 13/725382 [patent_app_country] => US [patent_app_date] => 2012-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 80513 [patent_no_of_claims] => 90 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13725382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10174953 [patent_doc_number] => 09205140 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-08 [patent_title] => 'MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer' [patent_app_type] => utility [patent_app_number] => 13/713753 [patent_app_country] => US [patent_app_date] => 2012-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 5435 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13713753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8767466 [patent_doc_number] => 20130095503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-18 [patent_title] => 'SERUM SPLA2-IIA AS DIAGNOSIS MARKER FOR PROSTATE AND LUNG CANCER' [patent_app_type] => utility [patent_app_number] => 13/707245 [patent_app_country] => US [patent_app_date] => 2012-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 20965 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13707245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9191008 [patent_doc_number] => 20130330324 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-12 [patent_title] => 'ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)' [patent_app_type] => utility [patent_app_number] => 13/693330 [patent_app_country] => US [patent_app_date] => 2012-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 62517 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13693330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8755191 [patent_doc_number] => 20130089496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-11 [patent_title] => 'TUMOR TARGETED ANTIBODIES AND METHOD FOR USING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/645814 [patent_app_country] => US [patent_app_date] => 2012-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17665 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13645814 [rel_patent_id] =>[rel_patent_doc_number] =>)